Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
It is a longstanding puzzle why non-coding variants in the complement factor H (CFH) gene are more strongly associated with age-related macular degeneration (AMD) than functional coding variants that directly influence the alternative complement pathway. The situation is complicated by tight genetic associations across the region, including the adjacent CFH-related genes CFHR3 and CFHR1, which may themselves influence the alternative complement pathway and are contained within a common deletion (CNP147) which is associated with protection against AMD. It is unclear whether this association is mediated through a protective effect of low plasma CFHR1 concentrations, high plasma CFH or both. We examined the triangular relationships of CFH/CFHR3/CFHR1 genotype, plasma CFH or CFHR1 concentrations and AMD susceptibility in combined case-control (1256 cases, 1020 controls) and cross-sectional population (n = 1004) studies and carried out genome-wide association studies of plasma CFH and CFHR1 concentrations. A non-coding CFH SNP (rs6677604) and the CNP147 deletion were strongly correlated both with each other and with plasma CFH and CFHR1 concentrations. The plasma CFH-raising rs6677604 allele and raised plasma CFH concentration were each associated with AMD protection. In contrast, the protective association of the CNP147 deletion with AMD was not mediated by low plasma CFHR1, since AMD-free controls showed increased plasma CFHR1 compared with cases, but it may be mediated by the association of CNP147 with raised plasma CFH concentration. The results are most consistent with a regulatory locus within a 32 kb region of the CFH gene, with a major effect on plasma CFH concentration and AMD susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Howie, B. N., Donnelly, P., & Marchini, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000529 · Cited by 3,928 · cited 2×
“Pre-phasing was performed using SHAPEIT2 (57) and imputation with IMPUTE2 (58,59).”
MethodSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Therapeutic use of CFH delivered by 2-weekly intravenous injection of fresh frozen plasma (half-life 6 days) (46) is not practicable on the necessary scale, but local delivery of an inducible recombinant CFH to the choroid or retinal pigment epithelium by a viral vector may be more achievable (47,48).”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Therapeutic use of CFH delivered by 2-weekly intravenous injection of fresh frozen plasma (half-life 6 days) (46) is not practicable on the necessary scale, but local delivery of an inducible recombinant CFH to the choroid or retinal pigment epithelium by a viral vector may be more achievable (47,48).”
BackgroundSelf-citationGenABEL: an R library for genome-wide association analysis
Aulchenko, Y. S., Ripke, S., Isaacs, A., & van Duijn, C. M. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm108 · Cited by 1,836
Fast and accurate genotype imputation in genome-wide association studies through pre-phasing
Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., & Abecasis, G. R. (2012) · Nature Genetics · doi:10.1038/ng.2354 · Cited by 1,737 · cited 2×
“Pre-phasing was performed using SHAPEIT2 (57) and imputation with IMPUTE2 (58,59).”
MethodUsing multiple genetic variants as instrumental variables for modifiable risk factors
Palmer, T. M., Lawlor, D. A., Harbord, R. M., Sheehan, N. A., Tobias, J. H., Timpson, N. J., Smith, G. D., & Sterne, J. A. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280210394459 · Cited by 1,289
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 1×
“This pathway is strongly implicated in AMD risk (9), since several components are either present in diseased tissues, such as the characteristic extracellular drusen deposits (CFH, C3b/ iC3b, BF, C5b-9), or they are genetically associated with disease risk (C3, C2/BF, CFH, CFHR1, CFHR3, CFI) (10,11).”
BackgroundGenotype Imputation with Thousands of Genomes
Howie, B., Marchini, J., & Stephens, M. (2011) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.111.001198 · Cited by 966
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829 · cited 3×
“Subject recruitment has been described for the Croatian (26), Dutch (Rucphen) (27), SAMD (31) and EAMD (31) samples.”
BackgroundMethodSelf-citationMaller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D., Daly, M. J., & Seddon, J. M. (2006) · Nature Genetics · doi:10.1038/ng1873 · Cited by 599
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress
Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P. N., Issa, P. C., Cano, M., Brandstätter, H., Tsimikas, S., Skerka, C., et al. (2011) · Nature · doi:10.1038/nature10449 · Cited by 533
Hughes, A. E., Orr, N., Esfandiary, H., Diaz-Torres, M., Goodship, T., & Chakravarthy, U. (2006) · Nature Genetics · doi:10.1038/ng1890 · Cited by 467
Li, M., Atmaca-Sonmez, P., Othman, M., Branham, K. E. H., Khanna, R., Wade, M. S., Li, Y., Liang, L., Zareparsi, S., Swaroop, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1871 · Cited by 354 · cited 4×
“Subsequent analyses, however, showed that the strongest associations with AMD across the CFH-CFHR3-CFHR1 region were independent of the CNP147 deletion (23,24) and resulted from non-coding or synonymous variants lying within a small 32 kb region in the CFH gene between rs203687 in intron 9 and rs1329427 in intron 15 (…”
BackgroundInfluentialDespriet, D. D. G., Klaver, C. C. W., Witteman, J. C. M., Bergen, A. A. B., Kardys, I., de Maat, M. P. M., Boekhoorn, S. S., Vingerling, J. R., Hofman, A., Oostra, B. A., et al. (2006) · JAMA · doi:10.1001/jama.296.3.301 · Cited by 348 · cited 1×
“Prospective studies show that progression to advanced stages of AMD is strongly predicted by risk genotypes in two genomic regions: complement factor H (CFH, OMIM #134370) and ARMS2/ HTRA1 (OMIM #611313) (4,5).”
BackgroundSelf-citationAssociation of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration
Seddon, J. M., Francis, P. J., George, S., Schultz, D. W., Rosner, B., & Klein, M. L. (2007) · JAMA · doi:10.1001/jama.297.16.1793 · Cited by 330 · cited 2×
“Prospective studies show that progression to advanced stages of AMD is strongly predicted by risk genotypes in two genomic regions: complement factor H (CFH, OMIM #134370) and ARMS2/ HTRA1 (OMIM #611313) (4,5).”
BackgroundResultA rare penetrant mutation in CFH confers high risk of age-related macular degeneration
Raychaudhuri, S., Iartchouk, O., Chin, K., Tan, P. L., Tai, A. K., Ripke, S., Gowrisankar, S., Vemuri, S., Montgomery, K., Yu, Y., et al. (2011) · Nature Genetics · doi:10.1038/ng.976 · Cited by 323 · cited 1×
“Mutations in CFH are also implicated in the renal disorders type II membranoproliferative glomerulonephritis and atypical haemolytic–uraemic syndrome (aHUS) (8), and one rare variant is implicated in causing both AMD and aHUS (12).”
BackgroundReynolds, R., Hartnett, M. E., Atkinson, J. P., Giclas, P. C., Rosner, B., & Seddon, J. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3928 · Cited by 294
McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278
Fritsche, L. G., Lauer, N., Hartmann, A., Stippa, S., Keilhauer, C. N., Oppermann, M., Pandey, M. K., Köhl, J., Zipfel, P. F., Weber, B. H. F., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq399 · Cited by 203
Self-citationStructural basis for complement factor H linked age-related macular degeneration
Prosser, B. E., Johnson, S., Roversi, P., Herbert, A. P., Blaum, B. S., Tyrrell, J., Jowitt, T. A., Clark, S. J., Tarelli, E., Uhrín, D., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071069 · Cited by 184
Self-citationBringing age-related macular degeneration into focus
Allikmets, R., & Dean, M. (2008) · Nature Genetics · doi:10.1038/ng0708-820 · Cited by 26
Cited by
Current Understanding of the Role of Complement in IgA Nephropathy
Maillard, N., Wyatt, R. J., Julian, B. A., Kiryluk, K., Gharavi, A., Fremeaux-Bacchi, V., & Novak, J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101000 · Cited by 338
Regulation of regulators: Role of the complement factor H-related proteins
Cserhalmi, M., Papp, A., Brandus, B., Uzonyi, B., & Józsi, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101341 · Cited by 131
Implications of genetic variation in the complement system in age-related macular degeneration
de Jong, S., Gagliardi, G., Garanto, A., de Breuk, A., Lechanteur, Y. T. E., Katti, S., van den Heuvel, L. P., Volokhina, E. B., & den Hollander, A. I. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100952 · Cited by 71
Strunz, T., Lauwen, S., Kiel, C., International AMD Genomics Consortium (IAMDGC), Fritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58510-9 · Cited by 60
Self-citationTzoumas, N., Hallam, D., Harris, C. L., Lako, M., Kavanagh, D., & Steel, D. H. W. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.10.008 · Cited by 33
Metadata
- Authors
- Ansari, M., Mckeigue, P. M., Skerka, C., Hayward, C., Rudan, I., Vitart, V., Polasek, O., Armbrecht, A.-M., Yates, J. R. W., Vatavuk, Z., Bencic, G., Kolcic, I., Oostra, B. A., Van Duijn, C. M., Campbell, S., Stanton, C. M., Huffman, J., Shu, X., Khan, J. C., Shahid, H., Harding, S. P., Bishop, P. N., Deary, I. J., Moore, A. T., Dhillon, B., Rudan, P., Zipfel, P. F., Sim, R. B., Hastie, N. D., Campbell, H., & Wright, A. F.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-19
- Volume
- 22
- Issue
- 23
- Pages
- 4857-4869
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2165795903
- Cited by
- 88
- References
- 21
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.